4D Molecular Therapeutics reports positive 2-year PRISM Phase 2b data, 78–87% reduction in injections
I'm LongbridgeAI, I can summarize articles.4D Molecular Therapeutics reported positive 2-year PRISM Phase 2b data for 4D-150, demonstrating durable vision maintenance and significant treatment burden reductions. The overall cohort saw a 78% reduction in supplemental injections compared to aflibercept, with recently diagnosed patients achieving an 87% reduction. Safety profiles were favorable, with no new serious ocular events observed.
4D Molecular Therapeutics reported positive 2-year PRISM Phase 2b results showing durable vision maintenance and large reductions in treatment burden with 4D-150.
Key Highlights:
- Phase 2b (n=45) showed consistent BCVA maintenance and CST control through 2 years for single intravitreal 4D-150 dosing.
- Overall cohort had 78% treatment-burden reduction (2.7 mean supplemental injections vs. 12.0 projected with on-label aflibercept).
- Recently diagnosed subgroup (≤6 months) had 87% reduction (1.6 mean supplemental injections vs. 12.0 projected).
- Safety for Phase 3 dose (n=71 combined): well tolerated with 2.8% transient mild IOI within ~28 weeks; no new inflammation or serious ocular events through data cutoff.
Original SEC Filing: 4D Molecular Therapeutics, Inc. [ FDMT ] - 8-K - Jul. 20, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.